Android Apple

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

By Yahoo! Finance   |   1 month ago
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

Nuvectis Pharma, Inc. stock declined due to Phase 1b study results on NXP800 for ovarian cancer. Efficacy was observed with some patients showing tumor responses. The company plans to increase dosage intensity for better results.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.